Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Prioritisation programme:

Medicines evaluation

Rationale:

Review of TA987

Process:

Cost Comparison Standard

ID number:

6619

Project Team

Project lead

Leena Issa

Email enquiries

If you have any queries please email TACommC@nice.org.uk

External Assessment Group:

Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors

Bristol-Myers Squibb (lisocabtagene maraleucel)

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

Anthony Nolan

 

Blood Cancer UK

 

Lymphoma Action

Professional groups

Association of Cancer Physicians

 

Cancer Research UK

 

Clatterbridge Cancer Centre NHS Foundation Trust

 

Royal College of Pathologists

 

Royal College of Physicians

 

Royal College of Radiologists

Associated public health groups

None

Comparator companies

AbbVie (epcoritamab) (confidentiality agreement signed, participating)

 

Gilead Sciences (axicabtagene ciloleucel) (confidentiality agreement signed, participating)

 

Roche Products (rituximab, glofitamab, polatuzumab vedotin) (confidentiality agreement signed, participating)

 

Swedish Orphan Biovitrum (loncastuximab tesirine) (confidentiality agreement signed, participating)

 

Accord Healthcare (carboplatin, cisplatin, cytarabine, gemcitabine) (confidentiality agreement not signed, not participating)

 

Advanz Pharma (dexamethasone) (confidentiality agreement not signed, not participating)

 

Amarox (cisplatin, oxaliplatin) (confidentiality agreement not signed, not participating)

 

AS Kalceks (dexamethasone, oxaliplatin) (confidentiality agreement not signed, not participating)

 

Aspen (dexamethasone) (confidentiality agreement not signed, not participating)

 

Aspire Pharma (dexamethasone) (confidentiality agreement not signed, not participating)

 

Baxter Healthcare (ifosfamide) (confidentiality agreement not signed, not participating)

 

Celltrion Healthcare UK (rituximab) (confidentiality agreement not signed, not participating)

 

Chemidex Pharma (dexamethasone) (confidentiality agreement not signed, not participating)

 

Dr. Reddy’s Laboratories (UK) (bendamustine, rituximab) (confidentiality agreement not signed, not participating)

 

Ennogen Healthcare International (dexamethasone) (confidentiality agreement not signed, not participating)

 

Glenmark Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)

 

Hameln Pharma (dexamethasone) (confidentiality agreement not signed, not participating)

 

Hospira UK (carboplatin, cisplatin, cytarabine, dexamethasone, gemcitabine) (confidentiality agreement not signed, not participating)

 

Jazz Pharmaceuticals UK (cytarabine) (confidentiality agreement not signed, not participating)

 

KrKa UK (dexamethasone) (confidentiality agreement not signed, not participating)

 

Martindale Pharma (dexamethasone) (confidentiality agreement not signed, not participating)

 

Medac Pharma (epirubicin, oxaliplatin) (confidentiality agreement not signed, not participating)

 

Napp Pharmaceuticals (rituximab) (confidentiality agreement not signed, not participating)

 

Neon Healthcare (etoposide) (confidentiality agreement not signed, not participating)

 

Novartis Pharmaceuticals UK (dexamethasone) (confidentiality agreement not signed, not participating)

 

Panpharma UK (dexamethasone) (confidentiality agreement not signed, not participating)

 

Pfizer (cytarabine, epirubicin, methylprednisolone, rituximab) (confidentiality agreement not signed, not participating)

 

Rayner Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)

 

Rosemont Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)

 

Sandoz (cisplatin, rituximab) (confidentiality agreement not signed, not participating)

 

Seacross Phramaceuticals (bendamustine, epirubicin, oxaliplatin) (confidentiality agreement not signed, not participating)

 

Sun Pharmaceutical (gemcitabine, oxaliplatin) (confidentiality agreement not signed, not participating)

 

Synchrony Pharma (dexamethasone, gemcitabine) (confidentiality agreement not signed, not participating)

 

Thame Laboratories (dexamethasone) (confidentiality agreement not signed, not participating)

 

Thea Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)

 

Wockhardt UK (dexamethasone) (confidentiality agreement not signed, not participating)

 

Zentiva (dexamethasone) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics & Toxicology Centre

 

British National Formulary

 

Department of Health - Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Scottish Medicines Consortium

 

Welsh Government

Relevant research groups

Institute of Cancer Research

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual